We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study.
- Authors
Saito, Takuro; Kurokawa, Yukinori; Fujitani, Kazumasa; Kawabata, Ryohei; Takeno, Atsushi; Mikami, Jota; Endo, Shunji; Matsuyama, Jin; Akamaru, Yusuke; Hirota, Masashi; Kishi, Kentaro; Urakawa, Shinya; Yamamoto, Kei; Tanaka, Koji; Takahashi, Tsuyoshi; Oka, Mikio; Wada, Hisashi; Eguchi, Hidetoshi; Doki, Yuichiro
- Abstract
Background: No reliable marker has been identified to predict postoperative recurrence of gastric cancer. We designed a clinical trial to investigate the utility of serum NY-ESO-1 antibody responses as a predictive marker for postoperative recurrence in gastric cancer. Methods: A multicenter prospective study was conducted between 2012 and 2021. Patients with resectable cT3-4 gastric cancer were included. Postoperative NY-ESO-1 and p53 antibody responses were serially evaluated every 3 months for 1 year in patients with positive preoperative antibody responses. The recurrence rate was assessed by the positivity of antibody responses at 3 and 12 months postoperatively. Results: Among 1001 patients, preoperative NY-ESO-1 and p53 antibody responses were positive in 12.6% and 18.1% of patients, respectively. NY-ESO-1 antibody responses became negative postoperatively in non-recurrent patients (negativity rates; 45% and 78% at 3 and 12 months, respectively), but remained positive in recurrent patients (negativity rates; 9% and 8%, respectively). p53 antibody responses remained positive in non-recurrent patients. In multivariate analysis, NY-ESO-1 antibody positivity at 3 months (P < 0.03) and 12 months (P < 0.001) were independent prognostic factors for a shorter recurrence-free interval. Conclusions: Serum NY-ESO-1 antibodies may be a useful predictive marker for postoperative recurrence in gastric cancer. Clinical trial registration: UMIN000007925.
- Publication
British Journal of Cancer, 2024, Vol 130, Issue 7, p1157
- ISSN
0007-0920
- Publication type
Article
- DOI
10.1038/s41416-023-02540-3